Results 81 to 90 of about 1,044,818 (308)

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Monoclonal antibodies against human astrocytomas and their reactivity pattern [PDF]

, 1987
The establishment of hybridomas after fusion of X63-Ag8.653 mouse myeloma cells and splenocytes from mice hyperimmunized against human astrocytomas is presented. The animals were primed with 5 × 106 chemically modified uncultured or cultured glioma cells.
B. Martin, Bourdon, Bullard, Bullard, Carrel, Coakham, Coakham, D. Stavrou, De Muralt, E. Keiditsch, Epenetos, F. Schmidberger, I. Funke, Jonak, K. Bise, Kearney, Kemshead, Krajewski, Köhler, Lanier, Posner, R. Kurrle, Roholl, Schnegg, Seeger, Sikora, Stavrou, Stavrou, Stavrou, Stavrou, Stavrou, Stavrou, Stavrou, Taub, U. Stocker, W. Eisenmenger, Wikstrand   +36 more
core   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Antigen-specific electrophoretic cell separation for immunological investigations [PDF]

, 1989
Preincubation of human blood lymphocytes with cell surface antigen specific antibodies under non-capping conditions reduces the electrophoretic mobility of the corresponding lymphocyte subpopulation.
Hannig, K., Hansen, Ernil, Wustrow, T. P.   +2 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Monoclonal antibodies for the identification of New World Leishmania species

Memorias do Instituto Oswaldo Cruz, 1996
Monoclonal antibodies specific for selected species complexes of Leishmania have been employed for the characterization of several representative strains of Leishmania isolated from different hosts and localities in the Americas.
Gabriel Grimaldi Jr, Diane McMahon-Pratt
doaj   +1 more source

Use of OKT3 with ciclosporin and steroids for reversal of acute kidney and liver allograft rejection [PDF]

, 1987
OKT3 monoclonal antibody therapy was added to preexisting baseline immunosuppressive treatment with ciclosporin and steroids to treat rejection in 52 recipients of cadaveric livers and 10 recipients of cadaveric kidneys.
Demetris, AJ, Fung, JJ, Porter, KA
core   +1 more source

Emerging strategies to target metastasis and therapy resistance in melanoma

Molecular Oncology, EarlyView.
Emerging studies propose new approaches to interfere with melanoma progression. In recognition of melanoma awareness month, at Molecular Oncology, we highlight recently published research articles, focusing on novel therapeutic targets driving metastatic spread and outlining different strategies to overcome resistance to BRAF inhibitors and anti‐PD‐1 ...
Amel Aziba
wiley   +1 more source

Immunochemistry of human Lp[a]: characterization of monoclonal antibodies that cross-react strongly with plasminogen.

Journal of Lipid Research, 1991
Forty different monoclonal antibodies were produced from hybridomas that were raised against human Lp[a]. Of these, 14 strongly cross-reacted with plasminogen on ELISA screening assays while 16 clearly did not and 10 were only marginally cross-reactive ...
MA Lafferty, AM Salamon, DC Usher
doaj   +1 more source

Monoclonal Antibodies against the Drosophila Nervous System [PDF]

, 1982
A panel of 148 monoclonal antibodies directed against Drosophila neural antigens has been prepared by using mice immunized with homogenates of Drosophila tissue. Antibodies were screened immunohistochemically on cryostat sections of fly heads.
Benzer, Seymour, Ferrús, Alberto, Fujita, Shinobu C., Shotwell, Sandra L., Zipursky, Stephen L.   +4 more
core   +1 more source